1 郑洁.阿克曼外科病理学[M].北京:北京大学医学出版社,2014:1296-1302. 2 Liska J,Repiska V,Galbavy S,et al.Prostae tumours-histological classification and molecularaspects of prostate tumorigenesis[J].Endoer Regul,2007,41(2):45-57. 3 刘英娜,蒋智铭,冷冬妮.前列腺导管腺癌42例临床病理分析[J].临床与实验病理学杂志,2010,26(6):704-706. 4 Jiang Z,Li C,Ficher A,et al.Using an AMACR(P504S)/CK34βE12/p63 cocktail of small focal prostate carcinoma in needle biopay specimens[J].Am J Clin Pathol,2005,123(2):231-236. 5 刘彤华.诊断病理学[M].北京:人民卫生出版社,2012:544-549. 6 Herawi M,Epstein JI.Immunohistochemical antibody cocktail staining(P63/HNWCK/AMACR)of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinoma of prostate[J].Am J Surg Pathol,2007,31(7):889-894. 7 孙荣超,张丽华,杨树东.P504S、CK34βE12、p63、PSA在前列腺腺癌病理诊断中的应用[J].中华泌尿外科杂志,2006,27(12):847-850. 8 Wang TT,Xu C,Liu SL,et al.Clinicopathology,immunophenotype,T cell receptor gene rearrangement,Epstein-Barr virus status and p53 gene mutation of cutaneous extranodal NK/T-cell lymphoma,nasal-type[J].Chin Med J(Eng),2013,126(7):1281-1287. 9 Wang X,Jones TD.p53 expression in small cell carcinoma of the urinary bladder:biological and prognostic implications[J].Anticancer Res,2005,25(3B):2001-2004. 10 曹宇,古力米热,张正彪.p53基因在膀胱癌中的研究进展[J].中华现代外科学杂志,2008,10(5):737-741. 11 Kim JS,Ryu JG,Kim JW,et al.Prostae-specific antinen fluctuation:what does it mean in diagnosis of prostate cancer?[J].Int Braz J Uro,2015,41(2):258-264. 12 Pezaro C,Woo HH,Davis ID.Prostate cancer:measuring PSA[J].Intern Med J,2014,44(5):433-440. 13 Guttilla A,Zazzara M,Zzttoni F,et al.Histopathological characteristics of microfocal prostate cancer detected during systematic prostate biopsy[J].BJU Int,2015,116(2):202-206. 14 Bratt O,Folkvaljon Y,Loeb S,et al.Upper limit of cancer extent on biopsy defining very low-risk prostate cancer[J].BJU Int,2015,116(2):213-219. 15 吴超扬.帕米膦酸二钠联合化疗治疗骨癌转移性疼痛的疗效观察[J].中国实用医药,2015,10(18):151-152. |